Effect of cisplatin and c-myb antisense phosphorothioate oligodeoxynucleotides combination on a human colon carcinoma cell line in vitro and in vivo

D. Del Bufalo, C. Cucco, C. Leonetti, G. Citro, I. D'Agnano, M. Benassi, T. Geiser, G. Zon, B. Calabretta, G. Zupi

Research output: Contribution to journalArticlepeer-review

Abstract

We investigated the effect of c-myb antisense phosphorothioate oligodeoxynucleotides [(S)ODNs] and cisplatin (CDDP) combination on the human colon carcinoma cell line LoVo Dx both in vitro and in nude mice bearing LoVo Dx solid tumour. We show that antisense (S)ODN treatment decreases c-myb mRNA and protein expression, induces growth arrest in the G1 phase of the cell cycle, and inhibits cell proliferation. In vivo treatment with c-myb antisense (S)ODNs results in a reduction in tumour growth. A greater inhibition of cell proliferation in vitro and a higher increase of tumour growth inhibition and growth delay in vivo were obtained with the combination of (S)ODNs and CDDP than when the two agents were administered separately. This comparative study, using the same rumour cell line in vitro and in vivo, suggests that c-myb antisense (S)ODNs might be useful in the therapy of colon cancer in combination with antineoplastic drugs.

Original languageEnglish
Pages (from-to)387-393
Number of pages7
JournalBritish Journal of Cancer
Volume74
Issue number3
Publication statusPublished - 1996

Keywords

  • c-myb
  • Cisplatin
  • Colon carcinoma
  • LoVo Dx
  • Phosphorothioate oligodeoxynucleotide

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Fingerprint Dive into the research topics of 'Effect of cisplatin and c-myb antisense phosphorothioate oligodeoxynucleotides combination on a human colon carcinoma cell line in vitro and in vivo'. Together they form a unique fingerprint.

Cite this